Debut Plus

11.93

-0.05 -0.42%

10 Sept 2026

NSE Listed

LT-ASM · ASM 1
What does LT-ASM · ASM 1 mean?
BSE · Long Term Additional Surveillance Measure (ASM 1)LT-ASM is the joint SEBI/exchange framework for SUSTAINED abnormal price moves (contrast ST-ASM's 5–15-day spikes). Entry is beta-adjusted price variation versus the Nifty (e.g. 3-month high-low above 150% plus the stock's β × index move) along with client-concentration checks. Stages I–IV escalate from a 5% price band through 100% margin to Trade-for-Trade with an additional surveillance deposit. Practical meaning: the exchange still considers the price action abnormal — tighter bands and elevated margins continue even if another measure (like ESM) has lifted. A stock can sit under LT-ASM on both exchanges via either exchange's shortlisting; it is a preventive cost-of-speculation measure, not an adverse finding against the company.Criteria: High 3-month / 12-month high-low price variation, close-to-close price variation, client concentration, number of price-band hits, market-wide position limit and P/E — applied in graded Stages I–IV with escalating margin and price-band curbs.Exchange notice · 2026-08-28
NSE · Long Term Additional Surveillance Measure (ASM 1)LT-ASM is the joint SEBI/exchange framework for SUSTAINED abnormal price moves (contrast ST-ASM's 5–15-day spikes). Entry is beta-adjusted price variation versus the Nifty (e.g. 3-month high-low above 150% plus the stock's β × index move) along with client-concentration checks. Stages I–IV escalate from a 5% price band through 100% margin to Trade-for-Trade with an additional surveillance deposit. Practical meaning: the exchange still considers the price action abnormal — tighter bands and elevated margins continue even if another measure (like ESM) has lifted. A stock can sit under LT-ASM on both exchanges via either exchange's shortlisting; it is a preventive cost-of-speculation measure, not an adverse finding against the company.Criteria: High 3-month / 12-month high-low price variation, close-to-close price variation, client concentration, number of price-band hits, market-wide position limit and P/E — applied in graded Stages I–IV with escalating margin and price-band curbs.Exchange notice · 2026-08-31

Nectar Lifesciences Ltd. (NECLIFE)

Volume: 87,468Avg Vol 1W: 1,81,649Avg Vol 1M: 3,52,965.652W Range:9.322.4
Market Cap₹232 Cr
Current Price₹11.93
Previous Close₹11.98
High / Low (52w)₹22.4 / ₹9.3
Volume87,468
Avg Vol (1W)1,81,649
Avg Vol (1M)3,52,965.6
Stock P/E
Book Value₹29.97
Dividend Yield0%
ROE-9.85%
ROA-39.42%
Revenue (TTM)₹9 Cr
Revenue Growth-0.8%
Profit Margin-24,50,600%
Total Debt₹60 Cr
Shares Outstanding19 Cr
Face Value₹1
EPS (TTM)₹0
P/B0.4
Debt / Equity0.38
50 DMA₹11.13
200 DMA₹13.15
Day change-0.42%
SurveillanceLT-ASM · ASM 1
Price Chart
11.93 16.69% · 1Y
2295.3Cr
2025-09-10
2026-09-10

20-day avg volume: 3.5L shares

Pros
  • Company is almost debt-free.
  • Revenue grew 18% YoY.
  • Net profit is growing year over year.
  • Stock trades below its book value.
Quarterly Results
MetricSept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Revenue₹6 Cr₹0 Cr₹0 Cr₹5 Cr₹1 Cr₹0 Cr₹1 Cr₹0 Cr
EBITDA₹0 Cr₹0 Cr₹0 Cr₹-1 Cr₹0 Cr₹-1 Cr₹-51 Cr₹-24 Cr
Net Profit₹6 Cr₹8 Cr₹-130 Cr₹-63 Cr₹-176 Cr₹14 Cr₹-68 Cr₹-15 Cr
EPS
Profit & Loss (Annual)
MetricMar 2025Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Mar 2026Jun 2026
Revenue₹1,675 Cr₹0 Cr₹5 Cr₹1 Cr₹0 Cr₹1 Cr₹9 Cr₹0 Cr
EBITDA₹-87 Cr₹0 Cr₹-1 Cr₹0 Cr₹-1 Cr₹-51 Cr₹-52 Cr₹-21 Cr
Net Profit₹-114 Cr₹-130 Cr₹-63 Cr₹-176 Cr₹14 Cr₹-68 Cr₹-293 Cr₹-13 Cr
EPS-5.07-13.4
Balance Sheet
MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets₹2,705 Cr₹2,633 Cr₹2,471 Cr₹2,391 Cr₹2,189 Cr₹2,191 Cr₹2,047 Cr₹622 Cr
Total Liabilities₹1,600 Cr₹1,497 Cr₹1,409 Cr₹1,303 Cr₹1,125 Cr₹1,122 Cr₹1,091 Cr₹39 Cr
Equity₹1,105 Cr₹1,136 Cr₹1,062 Cr₹1,088 Cr₹1,065 Cr₹1,069 Cr₹956 Cr₹582 Cr
Total Debt
Cash Flow
MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating₹253 Cr₹294 Cr₹25 Cr₹95 Cr₹134 Cr₹225 Cr₹169 Cr₹-349 Cr
Investing₹-26 Cr₹-33 Cr₹-29 Cr₹17 Cr₹52 Cr₹-17 Cr₹-42 Cr₹1,208 Cr
Financing₹-201 Cr₹-252 Cr₹11 Cr₹-119 Cr₹-186 Cr₹-205 Cr₹-128 Cr₹-767 Cr
Free Cash Flow₹253 Cr₹294 Cr₹25 Cr₹95 Cr₹134 Cr₹225 Cr₹169 Cr₹-349 Cr
Shareholding
Promoter 51.84% Institutions 4.24% Public 43.91%
Efficiency & Working Capital
ROCE-8.7%
Interest Coverage0
Dividend Payout
Debtor Days
Inventory Days
Payable Days
Cash Conversion Cycle
Working Capital Days
Shareholding Details

As of 2026-06-30

Promoter51.8%
FII0.5%
DII3.7%
Institutions4.2%
Public43.9%
Promoter Pledge0%
No. of Shareholders73,834
Shareholding Pattern

Quarterly — figures in %. Latest 12 quarters.

PeriodMar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Jan 2026Jan 2026Mar 2026Jun 2026
Promoters55.8%55.8%55.8%44.5%44.5%44.5%44.9%44.9%51.8%51.8%51.8%51.8%
FIIs17%16.6%3.2%0.7%1.6%0.8%0.6%0.5%0.6%0.6%0.6%0.5%
DIIs0%0%0%0%0.2%0.2%0.1%5.8%3.5%3.5%4%3.7%
Public27.2%27.6%41%54.7%53.7%54.5%54.4%48.7%44%44%43.5%43.9%
Promoter Pledge100%100%100%99.6%99.6%99.6%98.8%0%0%0%0%0%
No. of Shareholders59,94658,23066,74169,48269,24171,97776,47078,12476,64876,64874,83473,834
Returns History (ROE / ROCE / ROA)
PeriodROEROCEROAP/E
202603
Major Shareholders (>1%)
NameCategoryStakeShares
Sanjiv GoyalShareholding of Promoter and Promoter Group24.6%4.78 Cr
Sanjiv (huf) - Karta Sanjiv GoyalShareholding of Promoter and Promoter Group22.5%4.36 Cr
Raman GoyalShareholding of Promoter and Promoter Group4.8%92,38,448
Rajasthan Global Securities Private LimitedPublic Shareholding3.7%72,47,763
Nectar Organics Private LimitedShareholding of Promoter and Promoter Group0%0
Orient Alloys Private LimitedShareholding of Promoter and Promoter Group0%0
Board of Directors
NameDesignationYear
Sanjiv GoyalChairman & Managing Director2025
Rupinder TewariIndependent Non Exe. Director2025
Kuldip Kumar BhasinIndependent Non Exe. Director2025
Indu Pal KaurIndependent Non Exe. Director2025
Surulichamy SenthilkumarExecutive Director2025
Sanjaymohan Singh RawatCompany Sec. & Compli. Officer2025
Sushil KapoorWTD & Director (Finance)2025
Segments — Product
SegmentRevenueShare
Pharmaceuticals Products₹0 Cr
Segments — Geography
RegionRevenueShare
India₹302 Cr64.2%
Outside India₹169 Cr35.8%
Capital Structure (₹ Cr)
YearFace ValueAuthorisedIssuedPaid-up
2026₹1351919
Corporate Actions
TypeDateValueRemark
forthcoming2026-08-14Board Meetings
buyback2026-01-06₹27 max
Related-Party Transactions (₹ Cr)
YearSubsidiariesAssociatesJVKMPOthersTotal
20269900150114
20269800140112
2026100102
Insider / Designated-Person Trades

5 recent disclosure(s)

Raman GoyalAcquisition · 80,00,000
Sanjiv GoyalDisposal · 80,00,000
SBICAP Trustee Company LimitedRevoke · 9,94,68,000
SanjivHUFRevoke · 4,36,22,400
Sanjiv GoyalRevoke · 5,58,45,600
Substantial Acquisitions (SAST)

3 disclosure(s)

Buy Back20/01/2026 ·
Market12/12/2025 · 3,62,422
Release Of Pledge30/10/2025 ·
Company Information
Incorporated1995
ChairmanSanjiv Goyal
AuditorDeepak Jindal & Co
Investor Email[email protected]
🌐 www.neclife.com

📍 Village Saidpura, Tehsil Derabassi S A S Nagar, Mohali, Punjab, 140507

Technical AnalysisPremium

Technical analysis (Premium)

Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.

More stocks

Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search